MDBH Earnings

MDBH reported its earnings on 2025-03-31, showcasing a revenue of 0.00 against an estimate of , resulting in a 0% surprise. The EPS was 2.88, surpassing the expected 0 by 0% . The stock experienced a 2.28% price change on the earnings day and a -6.65% change over the next five days, reflecting market reactions to the results.

Following MDBH's earnings announcement on 2025-03-31, the stock price moved by 2.28% on the day of the release. Over the subsequent five days, it saw a -6.65% change. Historically, MDBH's stock price tends to shift by an average of -0.37% in the 10 days leading up to earnings and -16.02% in the 10 days following, providing insight into potential market.

For , analysts estimate MDBH’s annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue Go Down by -4.18% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between MDBH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for were Go Down by -4.18%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MDBH's stock price typically moves by -0.37% in the 10 days before its earnings and -16.02% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call reveals mixed signals: while there are promising investments like eXoZymes and HeartBeam awaiting FDA approval, the company's financial performance is contingent on future revenue and financing. The Q&A highlights concerns about shareholder dilution and management's vague timelines. Although the potential for high returns exists, the lack of immediate catalysts and uncertainties around approvals and timelines suggest a neutral impact on stock price.